229 related articles for article (PubMed ID: 9597194)
1. The use of aspirin in polycythaemia vera and primary thrombocythaemia.
Willoughby S; Pearson TC
Blood Rev; 1998 Mar; 12(1):12-22. PubMed ID: 9597194
[TBL] [Abstract][Full Text] [Related]
2. Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera.
Michiels JJ; Berneman ZN; Schroyens W; Van Vliet HH
Platelets; 2004 Mar; 15(2):67-84. PubMed ID: 15154599
[TBL] [Abstract][Full Text] [Related]
3. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia.
Squizzato A; Romualdi E; Passamonti F; Middeldorp S
Cochrane Database Syst Rev; 2013 Apr; (4):CD006503. PubMed ID: 23633335
[TBL] [Abstract][Full Text] [Related]
4. Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives.
Landolfi R; Patrono C
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():83-6. PubMed ID: 8951777
[TBL] [Abstract][Full Text] [Related]
5. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia.
Squizzato A; Romualdi E; Middeldorp S
Cochrane Database Syst Rev; 2008 Apr; (2):CD006503. PubMed ID: 18425953
[TBL] [Abstract][Full Text] [Related]
6. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
[TBL] [Abstract][Full Text] [Related]
7. Antiplatelet therapy in the management of myeloproliferative neoplasms.
Alvarez-Larrán A; Besses C
Curr Hematol Malig Rep; 2014 Dec; 9(4):319-23. PubMed ID: 25120015
[TBL] [Abstract][Full Text] [Related]
8. [Prevention of vascular complications in polycythemia vera and primary thrombocythemia treated with low doses of acetylsalicylic acid].
Fröhli P; Graf C; Rhyner K
Schweiz Med Wochenschr; 1983 Nov; 113(44):1622-7. PubMed ID: 6685916
[TBL] [Abstract][Full Text] [Related]
9. Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies.
Landolfi R; Di Gennaro L; Novarese L; Patrono C
Semin Thromb Hemost; 2006 Apr; 32(3):251-9. PubMed ID: 16673279
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis and management of bleeding in essential thrombocythemia and polycythemia vera.
Elliott MA; Tefferi A
Curr Hematol Rep; 2004 Sep; 3(5):344-51. PubMed ID: 15341701
[TBL] [Abstract][Full Text] [Related]
11. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia.
Elliott MA; Tefferi A
Br J Haematol; 2005 Feb; 128(3):275-90. PubMed ID: 15667529
[TBL] [Abstract][Full Text] [Related]
12. ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera.
Panova-Noeva M; Marchetti M; Russo L; Tartari CJ; Leuzzi A; Finazzi G; Rambaldi A; ten Cate H; Falanga A
Thromb Res; 2013 Jul; 132(1):88-93. PubMed ID: 23735588
[TBL] [Abstract][Full Text] [Related]
13. Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia.
Vannucchi AM
Intern Emerg Med; 2010 Jun; 5(3):177-84. PubMed ID: 19789961
[TBL] [Abstract][Full Text] [Related]
14. European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP): a randomized trial.
Landolfi R; Marchioli R
Semin Thromb Hemost; 1997; 23(5):473-8. PubMed ID: 9387206
[TBL] [Abstract][Full Text] [Related]
15. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea.
Löfvenberg E; Wahlin A
Eur J Haematol; 1988 Oct; 41(4):375-81. PubMed ID: 3197824
[TBL] [Abstract][Full Text] [Related]
16. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of platelet function and pharmacological platelet inhibition in patients with myeloproliferative disorders using multiple electrode aggregometry.
Robier C; Neubauer M; Sternad H; Quehenberger F; Rainer F; Neumeister P
Thromb Res; 2010 Sep; 126(3):232-7. PubMed ID: 20630570
[TBL] [Abstract][Full Text] [Related]
18. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
[TBL] [Abstract][Full Text] [Related]
19. Treatment of polycythaemia vera and essential thrombocythaemia.
Tefferi A; Silverstein MN
Baillieres Clin Haematol; 1998 Dec; 11(4):769-85. PubMed ID: 10640216
[TBL] [Abstract][Full Text] [Related]
20. Acute coronary disease in essential thrombocythemia and polycythemia vera.
Rossi C; Randi ML; Zerbinati P; Rinaldi V; Girolami A
J Intern Med; 1998 Jul; 244(1):49-53. PubMed ID: 9698024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]